Linked Life Data

17230535

Source:http://linkedlifedata.com/resource/pubmed/id/17230535

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2007-3-13
pubmed:abstractText
We previously reported to identify SOX5 as a glioma antigen by serological screening using a testis cDNA library. The present study was designed to analyze SOX5 expression, its immunoreactivity, and the correlation between SOX5 IgG responses and clinical features in glioma patients to evaluate the possibility of its use as a diagnostic marker. Quantitative RT-PCR and Western blot analysis revealed that SOX5 was expressed in glioma tissues, but not in normal adult tissues, except in the testis. An immunohistochemical analysis showed that SOX5 was expressed in glioma cells, but only a few SOX5-positive cells were detected in non-neoplastic tissues from the cerebral cortex. IgG antibodies against SOX5 were detected in sera from 8 of the 27 glioma patients (27.6%), 0 of the 14 patients with other brain diseases (0%), 1 of the 54 other cancer patients (1.9%) and 1 of the 37 healthy individuals (2.7%). Patients with glioblastoma (GBM) who showed IgG responses against SOX5 exhibited significantly better survival periods than GBM patients without SOX5 antibodies. In summary, SOX5 is aberrantly expressed in glioma and can be recognized as a glioma antigen using IgGs from the sera of glioma patients. Furthermore, there is a statistically significant correlation between the presence of SOX5 IgGs and survival in GBM patients, suggesting that the glioma antigen SOX5 may be useful not only as a diagnostic marker, but also as a prognostic marker in glioma patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0020-7136
pubmed:author
pubmed:copyrightInfo
(c) 2007 Wiley-Liss, Inc.
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
120
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1704-11
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:17230535-Adolescent, pubmed-meshheading:17230535-Adult, pubmed-meshheading:17230535-Aged, pubmed-meshheading:17230535-Aged, 80 and over, pubmed-meshheading:17230535-Antibodies, Neoplasm, pubmed-meshheading:17230535-Antigens, Neoplasm, pubmed-meshheading:17230535-Brain Neoplasms, pubmed-meshheading:17230535-Child, pubmed-meshheading:17230535-Child, Preschool, pubmed-meshheading:17230535-DNA-Binding Proteins, pubmed-meshheading:17230535-Epitopes, pubmed-meshheading:17230535-Female, pubmed-meshheading:17230535-Gene Expression Regulation, Neoplastic, pubmed-meshheading:17230535-Glioma, pubmed-meshheading:17230535-Humans, pubmed-meshheading:17230535-Immunoglobulin G, pubmed-meshheading:17230535-Male, pubmed-meshheading:17230535-Middle Aged, pubmed-meshheading:17230535-Neoplasms, pubmed-meshheading:17230535-Nuclear Proteins, pubmed-meshheading:17230535-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:17230535-SOXD Transcription Factors, pubmed-meshheading:17230535-Transcription Factors
pubmed:year
2007
pubmed:articleTitle
Preferential expression and frequent IgG responses of a tumor antigen, SOX5, in glioma patients.
pubmed:affiliation
Neuroimmunology Research Group, Keio University School of Medicine, Tokyo 160-8582, Japan.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't